THERACLION N Inactive Instrument
THERACLION N Stock Euronext Paris
Equities
FR0010120402
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| Jun. 24 | Sonovein FDA Pivotal Study Treatments Completed: Theraclion Reaches Key Milestone on Schedule | CI |
| Jun. 07 | Theraclion: scientific publication hailed by stock market | CF |
| Sales 2021 | 1.48M 1.62M | Sales 2022 | 1.24M 1.35M | Capitalization | 26.15M 28.52M |
|---|---|---|---|---|---|
| Net income 2021 | -3M -3.27M | Net income 2022 | -4M -4.36M | EV / Sales 2021 | 24.8 x |
| Net Debt 2021 | 6.99M 7.62M | Net Debt 2022 | 6.52M 7.11M | EV / Sales 2022 | 26.4 x |
| P/E ratio 2021 |
-7.93
x | P/E ratio 2022 |
-5.35
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 71.21% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Deterre
CEO | Chief Executive Officer | - | 19-12-31 |
Gaylord Tallec
COO | Chief Operating Officer | - | - |
Jeremie Anquez
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ari Kellen
BRD | Director/Board Member | - | 19-02-12 |
Renaud Saleur
BRD | Director/Board Member | - | 18-01-31 |
Yann Duchesne
CHM | Chairman | 67 | 22-01-23 |
Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows:
- sale of equipment (66.1%);
- sale of consumables (27.8%);
- provision of after-sales services (6.1%).
Export accounts for 96.6% of net sales.
Calendar
2024-09-18
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +3.26% | 207B | |
| +6.55% | 182B | |
| +31.66% | 157B | |
| +34.32% | 113B | |
| +5.13% | 66.91B | |
| +19.33% | 55.95B | |
| -3.30% | 47.01B | |
| -4.84% | 38.17B | |
| +3.83% | 36.49B |
